Mongolia vs Mus: HIV-positive TB patients on ART (antiretroviral therapy)
Mongolia
100.0%
in 2024
Mus
100.0%
in 2024
Mongolia rank
1st
Mus rank
1st
HIV-positive TB patients on ART (antiretroviral therapy) over time
- Mongolia
- Mus
How they compare
Mongolia currently reports 100.0% against 100.0% in Mus, a difference of 0.0%.
The two have swapped places 5 times across 18 shared years of data; in 2005 it was Mongolia ahead.
Mongolia ranks 1st and Mus ranks 1st of 144 countries.
Across the 3 decades both report, Mongolia averaged higher in 1 and Mus in 1.
Head to head by decade
| Decade | Mongolia | Mus | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 83.2% | 66.5% | 16.8% | Mongolia |
| 2010s | 78.1% | 86.2% | 8.1% | Mus |
| 2020s | 100.0% | 100.0% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv-positive tb patients on art (antiretroviral therapy), Mongolia or Mus?
- Mongolia, at 100.0% against 100.0% in Mus as of 2024.
- What is the difference in hiv-positive tb patients on art (antiretroviral therapy) between Mongolia and Mus?
- 0.0%, with Mongolia ahead.
- How many years of comparable data are there for Mongolia and Mus?
- 18 years are reported by both, from 2005 to 2024.
- How do Mongolia and Mus rank globally for hiv-positive tb patients on art (antiretroviral therapy)?
- Mongolia ranks 1st and Mus ranks 1st of 144 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as HIV-positive TB patients on ART (antiretroviral therapy) (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.